Cargando…

Real‐World clinical features and survival outcomes associated with primary gastrointestinal natural killer/T‐cell lymphoma from 1999 to 2020

BACKGROUND: Primary gastrointestinal natural killer (NK)/T‐cell lymphoma (PGINKTL) is a rare T‐/NK‐cell lymphoma subtype, and the clinical features and survival outcomes remain largely unknown. METHODS: To summarize the clinical features and survival outcomes of PGINKTL, PGINKTL cases diagnosed at o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chunli, Yang, Ming, Jiang, Ziyan, Ma, Jie, Ji, Shuli, Lv, Jie, Huang, Yu, Wu, Caigang, Xu, Liqun, Zou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939185/
https://www.ncbi.nlm.nih.gov/pubmed/36114786
http://dx.doi.org/10.1002/cam4.5136
_version_ 1784890791970209792
author Chunli, Yang
Ming, Jiang
Ziyan, Ma
Jie, Ji
Shuli, Lv
Jie, Huang
Yu, Wu
Caigang, Xu
Liqun, Zou
author_facet Chunli, Yang
Ming, Jiang
Ziyan, Ma
Jie, Ji
Shuli, Lv
Jie, Huang
Yu, Wu
Caigang, Xu
Liqun, Zou
author_sort Chunli, Yang
collection PubMed
description BACKGROUND: Primary gastrointestinal natural killer (NK)/T‐cell lymphoma (PGINKTL) is a rare T‐/NK‐cell lymphoma subtype, and the clinical features and survival outcomes remain largely unknown. METHODS: To summarize the clinical features and survival outcomes of PGINKTL, PGINKTL cases diagnosed at our hospital from May 1999 to December 2020 were reviewed; and the clinical data, information on treatment strategies, and survival were collected. Survival analysis was performed using the Kaplan–Meier method and multivariable Cox proportional hazards regression. We constructed a nomogram to visualize the survival prediction of PGINKTL. The discriminative ability and calibration of the nomogram for prediction were tested using the concordance index (C‐index) and calibration plots. RESULTS: The cohort included 81 cases, the median age was 36 years (range, 7–80 years), and the male‐to‐female ratio was 1.7:1. The most common clinical symptom at the time of diagnosis was abdominal pain (71.6%). The most common lesion site was the colon (59.3%). During a median follow‐up period of 37.7 months, the median overall survival (OS) time of 81 patients was 4.0 months (95% confidence interval [CI], 3.1–4.9 months), and the 2‐year OS rate was 30.7% (95% CI, 20.3%–40.1%). The multivariate analyses indicated that patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score ≥2, serum lactic dehydrogenase (LDH) level ≥ the upper limit normal (ULN), and perforation had worse OS. We used these data to establish a nomogram to predict survival for PGINKTL. The nomogram displayed good accuracy, with a C‐index of 0.726. CONCLUSION: The clinical features and poor outcomes of PGINKTL, which is a rare and fatal lymphoma type, are presented. The proposed nomogram provides an individualized estimate of survival for these patients. In the future, the study focused on exploring a better treatment strategy to improve survival is required in PGINKTL.
format Online
Article
Text
id pubmed-9939185
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99391852023-02-20 Real‐World clinical features and survival outcomes associated with primary gastrointestinal natural killer/T‐cell lymphoma from 1999 to 2020 Chunli, Yang Ming, Jiang Ziyan, Ma Jie, Ji Shuli, Lv Jie, Huang Yu, Wu Caigang, Xu Liqun, Zou Cancer Med RESEARCH ARTICLES BACKGROUND: Primary gastrointestinal natural killer (NK)/T‐cell lymphoma (PGINKTL) is a rare T‐/NK‐cell lymphoma subtype, and the clinical features and survival outcomes remain largely unknown. METHODS: To summarize the clinical features and survival outcomes of PGINKTL, PGINKTL cases diagnosed at our hospital from May 1999 to December 2020 were reviewed; and the clinical data, information on treatment strategies, and survival were collected. Survival analysis was performed using the Kaplan–Meier method and multivariable Cox proportional hazards regression. We constructed a nomogram to visualize the survival prediction of PGINKTL. The discriminative ability and calibration of the nomogram for prediction were tested using the concordance index (C‐index) and calibration plots. RESULTS: The cohort included 81 cases, the median age was 36 years (range, 7–80 years), and the male‐to‐female ratio was 1.7:1. The most common clinical symptom at the time of diagnosis was abdominal pain (71.6%). The most common lesion site was the colon (59.3%). During a median follow‐up period of 37.7 months, the median overall survival (OS) time of 81 patients was 4.0 months (95% confidence interval [CI], 3.1–4.9 months), and the 2‐year OS rate was 30.7% (95% CI, 20.3%–40.1%). The multivariate analyses indicated that patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score ≥2, serum lactic dehydrogenase (LDH) level ≥ the upper limit normal (ULN), and perforation had worse OS. We used these data to establish a nomogram to predict survival for PGINKTL. The nomogram displayed good accuracy, with a C‐index of 0.726. CONCLUSION: The clinical features and poor outcomes of PGINKTL, which is a rare and fatal lymphoma type, are presented. The proposed nomogram provides an individualized estimate of survival for these patients. In the future, the study focused on exploring a better treatment strategy to improve survival is required in PGINKTL. John Wiley and Sons Inc. 2022-09-17 /pmc/articles/PMC9939185/ /pubmed/36114786 http://dx.doi.org/10.1002/cam4.5136 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Chunli, Yang
Ming, Jiang
Ziyan, Ma
Jie, Ji
Shuli, Lv
Jie, Huang
Yu, Wu
Caigang, Xu
Liqun, Zou
Real‐World clinical features and survival outcomes associated with primary gastrointestinal natural killer/T‐cell lymphoma from 1999 to 2020
title Real‐World clinical features and survival outcomes associated with primary gastrointestinal natural killer/T‐cell lymphoma from 1999 to 2020
title_full Real‐World clinical features and survival outcomes associated with primary gastrointestinal natural killer/T‐cell lymphoma from 1999 to 2020
title_fullStr Real‐World clinical features and survival outcomes associated with primary gastrointestinal natural killer/T‐cell lymphoma from 1999 to 2020
title_full_unstemmed Real‐World clinical features and survival outcomes associated with primary gastrointestinal natural killer/T‐cell lymphoma from 1999 to 2020
title_short Real‐World clinical features and survival outcomes associated with primary gastrointestinal natural killer/T‐cell lymphoma from 1999 to 2020
title_sort real‐world clinical features and survival outcomes associated with primary gastrointestinal natural killer/t‐cell lymphoma from 1999 to 2020
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939185/
https://www.ncbi.nlm.nih.gov/pubmed/36114786
http://dx.doi.org/10.1002/cam4.5136
work_keys_str_mv AT chunliyang realworldclinicalfeaturesandsurvivaloutcomesassociatedwithprimarygastrointestinalnaturalkillertcelllymphomafrom1999to2020
AT mingjiang realworldclinicalfeaturesandsurvivaloutcomesassociatedwithprimarygastrointestinalnaturalkillertcelllymphomafrom1999to2020
AT ziyanma realworldclinicalfeaturesandsurvivaloutcomesassociatedwithprimarygastrointestinalnaturalkillertcelllymphomafrom1999to2020
AT jieji realworldclinicalfeaturesandsurvivaloutcomesassociatedwithprimarygastrointestinalnaturalkillertcelllymphomafrom1999to2020
AT shulilv realworldclinicalfeaturesandsurvivaloutcomesassociatedwithprimarygastrointestinalnaturalkillertcelllymphomafrom1999to2020
AT jiehuang realworldclinicalfeaturesandsurvivaloutcomesassociatedwithprimarygastrointestinalnaturalkillertcelllymphomafrom1999to2020
AT yuwu realworldclinicalfeaturesandsurvivaloutcomesassociatedwithprimarygastrointestinalnaturalkillertcelllymphomafrom1999to2020
AT caigangxu realworldclinicalfeaturesandsurvivaloutcomesassociatedwithprimarygastrointestinalnaturalkillertcelllymphomafrom1999to2020
AT liqunzou realworldclinicalfeaturesandsurvivaloutcomesassociatedwithprimarygastrointestinalnaturalkillertcelllymphomafrom1999to2020